{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:07:07Z","timestamp":1785769627769,"version":"3.56.0"},"reference-count":79,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,11,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Although the seminal event in sickle cell disease is the polymerization of abnormal hemoglobin, the downstream pathophysiology of vasoocclusion results from heterotypic interactions between the altered, adhesive sickle cell red blood cells, neutrophils, endothelium, and platelets. Ischemia reperfusion injury, hemolysis, and oxidant damage all contribute to heightened inflammation and activation of the hemostatic system. These various pathways are the focus of emerging treatments with potential to ameliorate disease manifestations. This review summarizes the considerable progress in development of these agents despite challenges in selection of study end points and complex pathophysiology.<\/jats:p>","DOI":"10.1182\/asheducation-2018.1.493","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T18:13:59Z","timestamp":1555438439000},"page":"493-506","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":30,"title":["New insights into the pathophysiology and development of novel therapies for sickle cell disease"],"prefix":"10.1182","volume":"2018","author":[{"given":"Scott","family":"Moerdler","sequence":"first","affiliation":[{"name":"Children\u2019s Hospital, Montefiore Medical Center, Bronx, NY; and"},{"name":"Department of Microbiology and Immunology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Manwani","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital, Montefiore Medical Center, Bronx, NY; and"},{"name":"Division of Pediatric Hematology, Oncology, Marrow and Blood Cell Transplantation, Albert Einstein College of Medicine, Bronx, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"16","key":"2019111523021993800_B1","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJMra1510865","article-title":"Sickle cell disease","volume":"376","author":"Piel","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111523021993800_B2","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/003335491312800206","article-title":"Mortality rates and age at death from sickle cell disease: U.S., 1979-2005","volume":"128","author":"Lanzkron","year":"2013","journal-title":"Public Health Rep"},{"issue":"2","key":"2019111523021993800_B3","doi-asserted-by":"crossref","first-page":"94","DOI":"10.7326\/0003-4819-148-2-200801150-00004","article-title":"Daily assessment of pain in adults with sickle cell disease","volume":"148","author":"Smith","year":"2008","journal-title":"Ann Intern Med"},{"issue":"6","key":"2019111523021993800_B4","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S0891-5849(97)00391-2","article-title":"The molecular pathobiology of cell membrane iron: the sickle red cell as a model","volume":"24","author":"Browne","year":"1998","journal-title":"Free Radic Biol Med"},{"issue":"1-2","key":"2019111523021993800_B5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.tracli.2008.03.011","article-title":"Adhesion of sickle red cells to endothelium: myths and future directions","volume":"15","author":"Hebbel","year":"2008","journal-title":"Transfus Clin Biol"},{"issue":"10","key":"2019111523021993800_B6","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1182\/blood.V92.10.3924","article-title":"Interaction of sickle erythrocytes with endothelial cells in the presence of endothelial cell conditioned medium induces oxidant stress leading to transendothelial migration of monocytes","volume":"92","author":"Sultana","year":"1998","journal-title":"Blood"},{"issue":"6","key":"2019111523021993800_B7","doi-asserted-by":"crossref","first-page":"H2715","DOI":"10.1152\/ajpheart.00986.2004","article-title":"Critical role of endothelial cell activation in hypoxia-induced vasoocclusion in transgenic sickle mice","volume":"288","author":"Belcher","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"5","key":"2019111523021993800_B8","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1073\/pnas.052522799","article-title":"Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm","volume":"99","author":"Turhan","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"2019111523021993800_B9","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1182\/blood-2009-12-260513","article-title":"GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice","volume":"116","author":"Chang","year":"2010","journal-title":"Blood"},{"issue":"17","key":"2019111523021993800_B10","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/blood-2014-06-583351","article-title":"Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use","volume":"125","author":"Telen","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2019111523021993800_B11","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111523021993800_B12","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nm.1939","article-title":"Heterotypic interactions enabled by polarized neutrophil microdomains mediate thromboinflammatory injury","volume":"15","author":"Hidalgo","year":"2009","journal-title":"Nat Med"},{"issue":"2","key":"2019111523021993800_B13","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1182\/blood-2007-04-084061","article-title":"Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion","volume":"111","author":"Chang","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2019111523021993800_B14","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/ajh.23956","article-title":"Single-dose intravenous gammaglobulin can stabilize neutrophil Mac-1 activation in sickle cell pain crisis","volume":"90","author":"Manwani","year":"2015","journal-title":"Am J Hematol"},{"key":"2019111523021993800_B15","article-title":"Sevuparin blocks sickle blood cell adhesion and sickle-leukocyte rolling on immobilized L-selectin in a dose dependent manner [published online ahead of print 16 May 2018]","volume-title":"Br J Haematol","author":"White"},{"issue":"5","key":"2019111523021993800_B16","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/bjh.14303","article-title":"Sevuparin binds to multiple adhesive ligands and reduces sickle red blood cell-induced vaso-occlusion","volume":"175","author":"Telen","year":"2016","journal-title":"Br J Haematol"},{"key":"2019111523021993800_B17","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1182\/asheducation-2013.1.362","article-title":"Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies","volume":"2013","author":"Manwani","year":"2013","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"1","key":"2019111523021993800_B18","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/asheducation-2017.1.440","article-title":"Evolving treatment paradigms in sickle cell disease","volume":"2017","author":"Jagadeeswaran","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"2019111523021993800_B19","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1172\/JCI89741","article-title":"Intravascular hemolysis and the pathophysiology of sickle cell disease","volume":"127","author":"Kato","year":"2017","journal-title":"J Clin Invest"},{"issue":"2","key":"2019111523021993800_B20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/(SICI)1096-8652(199806)58:2<117::AID-AJH5>3.0.CO;2-V","article-title":"Oral L-glutamine therapy for sickle cell anemia: I. Subjective clinical improvement and favorable change in red cell NAD redox potential","volume":"58","author":"Niihara","year":"1998","journal-title":"Am J Hematol"},{"issue":"3","key":"2019111523021993800_B21","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1715971","article-title":"A phase 3 trial of l-glutamine in sickle cell disease","volume":"379","author":"Niihara","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111523021993800_B22","doi-asserted-by":"crossref","first-page":"870","DOI":"10.3324\/haematol.2015.124586","article-title":"Dietary \u03c9-3 fatty acids protect against vasculopathy in a transgenic mouse model of sickle cell disease","volume":"100","author":"Kalish","year":"2015","journal-title":"Haematologica"},{"issue":"1","key":"2019111523021993800_B23","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3945\/ajcn.112.036319","article-title":"Effect of omega-3 (n-3) fatty acid supplementation in patients with sickle cell anemia: randomized, double-blind, placebo-controlled trial","volume":"97","author":"Daak","year":"2013","journal-title":"Am J Clin Nutr"},{"issue":"6","key":"2019111523021993800_B24","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1055\/s-0037-1615948","article-title":"Reduction of pain episodes and prothrombotic activity in sickle cell disease by dietary n-3 fatty acids","volume":"85","author":"Tomer","year":"2001","journal-title":"Thromb Haemost"},{"issue":"7","key":"2019111523021993800_B25","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1600-0463.2011.02751.x","article-title":"Pilot study of omega-3 fatty acid supplements in sickle cell disease","volume":"119","author":"Okpala","year":"2011","journal-title":"APMIS"},{"issue":"1","key":"2019111523021993800_B26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/ajh.10321","article-title":"Effects of N-acetylcysteine on dense cell formation in sickle cell disease","volume":"73","author":"Pace","year":"2003","journal-title":"Am J Hematol"},{"issue":"7","key":"2019111523021993800_B27","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s00277-011-1404-z","article-title":"N-acetylcysteine reduces oxidative stress in sickle cell patients","volume":"91","author":"Nur","year":"2012","journal-title":"Ann Hematol"},{"key":"2019111523021993800_B28","article-title":"Effect of N-acetylcysteine on pain in daily life in patients with sickle cell disease: a randomised clinical trial [published online ahead of print 23 June 2017]","author":"Sins","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111523021993800_B29","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2009-02-205492","article-title":"NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-gamma and CXCR3 chemokines","volume":"114","author":"Wallace","year":"2009","journal-title":"Blood"},{"issue":"23","key":"2019111523021993800_B30","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1182\/blood-2010-06-290643","article-title":"Adenosine A2A receptors induced on iNKT and NK cells reduce pulmonary inflammation and injury in mice with sickle cell disease","volume":"116","author":"Wallace","year":"2010","journal-title":"Blood"},{"issue":"17","key":"2019111523021993800_B31","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1182\/blood-2012-11-465963","article-title":"Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson","volume":"121","author":"Field","year":"2013","journal-title":"Blood"},{"issue":"20","key":"2019111523021993800_B32","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1182\/bloodadvances.2017009613","article-title":"Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease","volume":"1","author":"Field","year":"2017","journal-title":"Blood Adv"},{"issue":"2","key":"2019111523021993800_B33","doi-asserted-by":"crossref","first-page":"e0171067","DOI":"10.1371\/journal.pone.0171067","article-title":"NNKTT120, an anti-iNKT cell monoclonal antibody, produces rapid and sustained iNKT cell depletion in adults with sickle cell disease","volume":"12","author":"Field","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"2019111523021993800_B34","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/jama.294.1.81","article-title":"Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease","volume":"294","author":"Morris","year":"2005","journal-title":"JAMA"},{"issue":"2","key":"2019111523021993800_B35","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.hoc.2013.11.008","article-title":"Alterations of the arginine metabolome in sickle cell disease: a growing rationale for arginine therapy","volume":"28","author":"Morris","year":"2014","journal-title":"Hematol Oncol Clin North Am"},{"issue":"6","key":"2019111523021993800_B36","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/jn\/138.6.1148","article-title":"C-reactive protein and interleukin-6 are decreased in transgenic sickle cell mice fed a high protein diet","volume":"138","author":"Archer","year":"2008","journal-title":"J Nutr"},{"issue":"9","key":"2019111523021993800_B37","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.3324\/haematol.2013.086637","article-title":"A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes","volume":"98","author":"Morris","year":"2013","journal-title":"Haematologica"},{"issue":"5","key":"2019111523021993800_B38","doi-asserted-by":"crossref","first-page":"e37439","DOI":"10.1371\/journal.pone.0037439","article-title":"Citrulline a more suitable substrate than arginine to restore NO production and the microcirculation during endotoxemia","volume":"7","author":"Wijnands","year":"2012","journal-title":"PLoS One"},{"issue":"7","key":"2019111523021993800_B39","doi-asserted-by":"crossref","first-page":"5217","DOI":"10.3390\/nu7075217","article-title":"Citrulline supplementation improves organ perfusion and arginine availability under conditions with enhanced arginase activity","volume":"7","author":"Wijnands","year":"2015","journal-title":"Nutrients"},{"key":"2019111523021993800_B40","article-title":"A phase 1 dose-finding study of intravenous L-citrulline in sickle cell disease: a potential novel therapy for sickle cell pain crisis [published online ahead of print 7 February 2018]","author":"Majumdar","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111523021993800_B41","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1165\/rcmb.2017-0292OC","article-title":"Nitric oxide-independent soluble guanylate cyclase activation improves vascular function and cardiac remodeling in sickle cell disease","volume":"58","author":"Potoka","year":"2018","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"suppl 1","key":"2019111523021993800_B42","article-title":"The clinical-stage sGC stimulator IW-1701 prevents increase of plasma biomarkers of intravascular inflammation and suppresses leukocyte- endothelial interactions in Tnf\u03b1-treated mice [abstract]","volume":"130","author":"Tchernychev","year":"2017","journal-title":"Blood"},{"issue":"22","key":"2019111523021993800_B43","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.268.268","article-title":"A novel, highly potent and selective PDE9 inhibitor for the treatment of sickle cell disease [abstract]","volume":"128","author":"McArthur","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2019111523021993800_B44","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1161\/01.STR.32.4.980","article-title":"Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice","volume":"32","author":"Amin-Hanjani","year":"2001","journal-title":"Stroke"},{"issue":"5","key":"2019111523021993800_B45","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1365-2141.2010.08480.x","article-title":"A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction","volume":"153","author":"Hoppe","year":"2011","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111523021993800_B46","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/bjh.14580","article-title":"Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial","volume":"177","author":"Hoppe","year":"2017","journal-title":"Br J Haematol"},{"issue":"11","key":"2019111523021993800_B47","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.3324\/haematol.2011.054957","article-title":"Atorvastatin reduces serum cholesterol and triglycerides with limited improvement in vascular function in adults with sickle cell anemia","volume":"97","author":"Bereal-Williams","year":"2012","journal-title":"Haematologica"},{"issue":"2","key":"2019111523021993800_B48","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1053\/j.seminhematol.2018.04.007","article-title":"Novel sickle cell disease therapies: targeting pathways downstream of sickling","volume":"55","author":"Morrone","year":"2018","journal-title":"Semin Hematol"},{"issue":"21","key":"2019111523021993800_B49","article-title":"A phase I trial of zileuton in sickle cell disease","volume":"122","author":"Mpollo","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2019111523021993800_B50","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/ajh.24742","article-title":"Inhaled steroids reduce pain and sVCAM levels in individuals with sickle cell disease: a triple-blind, randomized trial","volume":"92","author":"Glassberg","year":"2017","journal-title":"Am J Hematol"},{"issue":"7","key":"2019111523021993800_B51","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood.V92.7.2594","article-title":"Increased levels of endothelin-1 in plasma of sickle cell anemia patients","volume":"92","author":"Rybicki","year":"1998","journal-title":"Blood"},{"key":"2019111523021993800_B52","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.lfs.2016.04.001","article-title":"Endothelin receptor antagonists in sickle cell disease: a promising new therapeutic approach","volume":"159","author":"Fox","year":"2016","journal-title":"Life Sci"},{"issue":"2","key":"2019111523021993800_B53","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/bjh.15021","article-title":"Fetal haemoglobin induction in sickle cell disease","volume":"180","author":"Paikari","year":"2018","journal-title":"Br J Haematol"},{"issue":"9","key":"2019111523021993800_B54","doi-asserted-by":"crossref","first-page":"e1002382","DOI":"10.1371\/journal.pmed.1002382","article-title":"Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: a randomized phase 1 study","volume":"14","author":"Molokie","year":"2017","journal-title":"PLoS Med"},{"issue":"7","key":"2019111523021993800_B55","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/ajh.23457","article-title":"Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes","volume":"88","author":"Sheehan","year":"2013","journal-title":"Am J Hematol"},{"issue":"3","key":"2019111523021993800_B56","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/blood-2017-11-814335","article-title":"Metformin induces FOXO3-dependent fetal hemoglobin production in primary erythroid cells","volume":"132","author":"Zhang","year":"2018","journal-title":"Blood"},{"issue":"28","key":"2019111523021993800_B57","doi-asserted-by":"crossref","first-page":"12617","DOI":"10.1073\/pnas.1006774107","article-title":"Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease","volume":"107","author":"Bradner","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"2019111523021993800_B58","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.exphem.2017.02.003","article-title":"Pharmacological inhibition of LSD1 and mTOR reduces mitochondrial retention and associated ROS levels in the red blood cells of sickle cell disease","volume":"50","author":"Jagadeeswaran","year":"2017","journal-title":"Exp Hematol"},{"issue":"3","key":"2019111523021993800_B59","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1182\/blood-2015-02-626259","article-title":"The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell mice","volume":"126","author":"Cui","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2019111523021993800_B60","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/bjh.14214","article-title":"GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease","volume":"175","author":"Oksenberg","year":"2016","journal-title":"Br J Haematol"},{"issue":"23","key":"2019111523021993800_B61","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.542.542","article-title":"GBT440, a potent anti-sickling hemoglobin modifier reduces hemolysis, improves anemia and nearly eliminates sickle cells in peripheral blood of patients with sickle cell disease [abstract]","volume":"126","author":"Lehrer-Graiwer","year":"2015","journal-title":"Blood"},{"issue":"suppl 1","key":"2019111523021993800_B62","article-title":"Initial results from a cohort in a phase 2a study (GBT440-007) evaluating adolescents with sickle cell disease treated with multiple doses of GBT440, a HbS polymerization inhibitor [abstract]","volume":"130","author":"Hoppe","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2019111523021993800_B63","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bjhh.2016.08.004","article-title":"A phase Ib open label, randomized, safety study of SANGUINATE\u2122 in patients with sickle cell anemia","volume":"39","author":"Misra","year":"2017","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"suppl 1","key":"2019111523021993800_B64","article-title":"Pegylated carboxyhemoglobin bovine (SANGUINATE\u00ae) restores RBCs roundness and reduces pain during a sickle cell vaso-occlusive crisis [abstract]","volume":"130","author":"Buontempo","year":"2017","journal-title":"Blood"},{"issue":"22","key":"2019111523021993800_B65","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.121.121","article-title":"SCD-101: a new anti-sickling drug reduces pain and fatigue and improves Red blood cell shape in peripheral blood of patients with sickle cell disease [abstract]","volume":"128","author":"Swift","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2019111523021993800_B66","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.blre.2015.12.003","article-title":"Coagulation abnormalities of sickle cell disease: relationship with clinical outcomes and the effect of disease modifying therapies","volume":"30","author":"Noubouossie","year":"2016","journal-title":"Blood Rev"},{"issue":"2","key":"2019111523021993800_B67","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1160\/Th06-12-0718","article-title":"Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial","volume":"98","author":"Qari","year":"2007","journal-title":"Thromb Haemost"},{"issue":"7","key":"2019111523021993800_B68","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1512021","article-title":"A multinational trial of prasugrel for sickle cell vaso-occlusive events","volume":"374","author":"Heeney","year":"2016","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2019111523021993800_B69","article-title":"Pharmacokinetics, pharmacodynamics and safety of ticagrelor in children with sickle cell disease: results of a two-part phase 2 study [abstract]","volume":"130","author":"Hsu","year":"2017","journal-title":"Blood"},{"issue":"22","key":"2019111523021993800_B70","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1182\/blood-2017-05-782003","article-title":"Targeting novel mechanisms of pain in sickle cell disease","volume":"130","author":"Tran","year":"2017","journal-title":"Blood"},{"key":"2019111523021993800_B71","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.cyto.2016.03.016","article-title":"Sickle red cells as danger signals on proinflammatory gene expression, leukotriene B4 and interleukin-1 beta production in peripheral blood mononuclear cell","volume":"83","author":"Pitanga","year":"2016","journal-title":"Cytokine"},{"issue":"1","key":"2019111523021993800_B72","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.trsl.2015.07.001","article-title":"Inflammatory targets of therapy in sickle cell disease","volume":"167","author":"Owusu-Ansah","year":"2016","journal-title":"Transl Res"},{"issue":"21","key":"2019111523021993800_B73","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.848.848","article-title":"Anti-interleukin-1\u03b2 antibody-based therapy ameliorates endothelial activation and inflammation in sickle mice [abstract]","volume":"118","author":"Kaul","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2019111523021993800_B74","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1111\/pme.12520","article-title":"Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients","volume":"15","author":"Daitch","year":"2014","journal-title":"Pain Med"},{"issue":"4","key":"2019111523021993800_B75","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/1740774516636573","article-title":"Addressing challenges of clinical trials in acute pain: The Pain Management of Vaso-occlusive Crisis in Children and Young Adults with Sickle Cell Disease Study","volume":"13","author":"Nottage","year":"2016","journal-title":"Clin Trials"},{"issue":"7","key":"2019111523021993800_B76","doi-asserted-by":"crossref","first-page":"e101301","DOI":"10.1371\/journal.pone.0101301","article-title":"Phase 1 study of the E-selectin inhibitor GMI 1070 in patients with sickle cell anemia [published correction appears in PLoS One. 2014;9(10):e111690]","volume":"9","author":"Wun","year":"2014","journal-title":"PLoS One"},{"issue":"22","key":"2019111523021993800_B77","article-title":"Phase 3 study of L-glutamine therapy in sickle cell anemia and sickle \u03b20-thalassemia subgroup analyses show consistent clinical improvement","volume":"128","author":"Yutaka","year":"2016","journal-title":"Blood"},{"issue":"15","key":"2019111523021993800_B78","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/bloodadvances.2018021444","article-title":"Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial)","volume":"2","author":"Daak","year":"2018","journal-title":"Blood Adv"},{"issue":"5","key":"2019111523021993800_B79","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1365-2141.2010.08395.x","article-title":"A randomized phase II trial of arginine butyrate with standard local therapy in refractory sickle cell leg ulcers","volume":"151","author":"McMahon","year":"2010","journal-title":"Br J Haematol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2018\/1\/493\/1253192\/hem01867.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2018\/1\/493\/1253192\/hem01867.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T00:19:15Z","timestamp":1573863555000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2018\/1\/493\/277584\/New-insights-into-the-pathophysiology-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,30]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,11,30]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2018.1.493","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,30]]}}}